Janelle Hart

"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.

In this interview, coauthors Connie Huang, MD, and Jason M. Kim, MD, discuss the findings of their recent study, "Urinary Tract Infection on social media: Examining YouTube content as a source of patient educational information."

"The biggest improvement in my patients has been the urgency frequency and urgency incontinence, and even some of the patients with irritable bowel," says David W. Law, DO.

"With the existing drugs, we are looking to make them better," said Scott T. Tagawa, MD.

Ekene Enemchukwu, MD, MPH, highlights her presentation, "Microaggressions 2.0 – How to survive and thrive," from the 2022 SUFU winter meeting.

Neal D. Shore, MD, discusses findings from the ARAMIS trial showing that patients with nmCRPC who have multiple comorbidities still respond well to darolutamide.

Elisabeth M. Sebesta, MD, coauthor of a recent study, reported that patients who experienced more unmet social needs were at increased risk of multiple urologic conditions, such as overactive bladder, interstitial cystitis, or urge incontinence.

In an interview with Urology Times, Raj S. Pruthi, MD, MHA, FACS, discusses the long-standing stigma of mental health and seeking care for emotional distress as a physician.

Urology Times interviewed co-author Fred Saad, MD, FRCS, on the importance of the ARASENS trial and the potential of triplet therapy as the future standard of care for metastatic hormone-sensitive prostate cancer.

In this interview, Toby C. Chai, MD, discusses the main takeaways from his presentation on imposter syndrome, personal experiences with imposter syndrome, and ways that physicians can avoid and or/resolve this negative feeling.

William K. Oh, MD, discussed oligometastatic prostate cancer in a recent presentation at the 2022 New York GU Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies.

Although testicular cancer is rare, it is a disease that providers and patients should still be aware of, says Bradley C. Leibovich, MD, FACS.

Casey Seideman, MD, advocates for an online presence in a recent presentation given at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference, titled “Social media as an avenue for justice.”

In the PROpel study, which was presented at the 2022 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, FRCS, and a team of investigators evaluated the efficacy of olaparib plus abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

In this interview interview, Randy Vince Jr, MD, gives an overview of the article, "A call for change: Why I can’t ‘celebrate’ with the AUA,” and advises fellow urologists on becoming a part of the movement to diversify the field.

In this interview, Andrea Staack, MD, PhD, discusses the background, findings, and takeaways of the study, "Mindfulness based-stress reduction is associated with decreased levels of patients’ anxiety after urodynamics- A prospective randomized controlled trial," along with why urologists should consider implementing more strategies of this effect in their practices.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Susan F. Slovin, MD, PhD, gave a presentation on immunotherapy in advanced prostate cancer.

In this interview, Omar El Shahawy, MD, MPH, PhD, discusses patient counseling in regard to e-cigarette use or vaping by using data from a recent study on evaluating the association of e-cigarette use and erectile dysfunction.

Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.

At the 2022 NY GU Cancers Symposium, Jean Hoffman-Censits, MD, discussed the latest developments in the neoadjuvant and adjuvant setting for patients with bladder cancer.

The BLASST-1 study presented at the 2022 ASCO Genitourinary Cancers Symposium assessed the safety and efficacy of neoadjuvant nivolumab in combination with gemcitabine/cisplatin in patients with muscle-invasive bladder cancer .

Min Dong, PhD, discusses the main points of the presentation he gave at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, along with the potential impact of onabotulinumtoxinA (Botox) therapies on future urologic treatment.

In this interview, Ashley Winter, MD, discusses why urologists should play a role in the management of STDs and STIs, especially when it comes to destigmatizing them.

"We shouldn't outright provide a negative attitude to our patients who are looking for alternatives that [serve as] complementary medicine, [like] herbal or phytotherapeutic agents," says J. Curtis Nickel, MD, FRCSC.

In this interview, Brian D. Gonzalez, PhD, shares results that were presented at the 2022 ASCO Genitourinary Cancers Symposium from the study, "Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer."

"Despite the existence of validated assessment tools, the impact of cystectomy on female sexual function remains scarcely investigated," the authors write.

A study presented at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting evaluated the safety and efficacy of percutaneous tibial nerve stimulation (PTNS) in patients who suffer from female sexual dysfunction.

In this interview, senior author and scientific principal investigator Seth P. Lerner, MD, discusses the results of the OLYMPUS trial and what they mean for the management of this disease